肺動脈高壓靶向藥物在慢性血栓栓塞性肺動脈高壓中的應用現狀_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

張泰隆 , 何康 ,  武忠

四川大學華西醫院心臟大血管外科（四川成都 610041）;

Corresponding?author：

武忠, Email: wuzhong71@163.com

Keywords：

DOI：

10.7507/1671-6205.202201002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 張泰隆, 何康, 武忠. 肺動脈高壓靶向藥物在慢性血栓栓塞性肺動脈高壓中的應用現狀. Chinese Journal of Respiratory and Critical Care Medicine, 2022, 21(8): 602-608. doi: 10.7507/1671-6205.202201002 Copy

1.	Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 2019, 53(1): 1801913.
2.	Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J, 2016, 37(1): 67-119.
3.	Simonneau G, Torbicki A, Dorfmüller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev, 2017, 26(143): 160112.
4.	Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar. J Am Coll Cardiol, 2020, 76(18): 2155-2169.
5.	Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest, 2001, 119(3): 818-823.
6.	Taniguchi Y, Ja?s X, Jevnikar M, et al. Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant, 2019, 38(8): 833-842.
7.	中華醫學會呼吸病學分會肺栓塞與肺血管病學組, 中國醫師協會呼吸醫師分會肺栓塞與肺血管病工作委員會, 全國肺栓塞與肺血管病防治協作組, 等. 中國肺動脈高壓診斷與治療指南(2021版). 中華醫學雜志, 2021, 101(1): 11-51.
8.	Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2, 700 patients. Ann Thorac Surg, 2012, 94(1): 97-103.
9.	Cannon JE, Su L, Kiely DG, et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy. Circulation, 2016, 133(18): 1761-1771.
10.	Hu S, Tan JS, Liu S, et al. The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China. J Thromb Thrombolysis, 2022, 53(4): 926-933.
11.	Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J, 2019, 53(1): 1801915.
12.	Aoki T, Sugimura K, Tatebe S, et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. Eur Heart J, 2017, 38(42): 3152-3159.
13.	Ja?s X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med, 2022, 10(10): 961-971.
14.	Sommer N, Ghofrani HA, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol, 2021, 178(1): 6-30.
15.	Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol, 2019, 176(8): 1038-1050.
16.	Seo B, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation, 1994, 89(3): 1203-1208.
17.	Dai Y, Chen X, Song XX, et al. Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension. J Am Coll Cardiol, 2019, 73(20): 2567-2580.
18.	Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ (Clinical research ed), 2018, 360: j5492.
19.	Zolty R. Pulmonary arterial hypertension specific therapy: The old and the new. Pharmacol Ther, 2020, 214: 107576,epub.
20.	Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation, 2011, 123(20): 2263-2273.
21.	Pichl A, Sommer N, Bednorz M, et al. Riociguat for treatment of pulmonary hypertension in COPD: a translational study. Eur Respir J, 2019, 53(6): 1802445.
22.	Kim NH. Group 4 pulmonary hypertension: chronic thromboembolic pulmonary hypertension: epidemiology, pathophysiology, and treatment. Cardiol Clin, 2016, 34(3): 435-441.
23.	Howden EJ, Ruiz-Carmona S, Claeys M, et al. Oxygen pathway limitations in patients with chronic thromboembolic pulmonary hypertension. Circulation, 2021, 143(21): 2061-2073.
24.	Miao R, Dong XB, Gong JN, et al. Examining the development of chronic thromboembolic pulmonary hypertension at the single-cell level. Hypertension, 2022, 79(3): 562-574.
25.	Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J, 2013, 41(2): 462-468.
26.	Southwood M, MacKenzie Ross RV, Kuc RE, et al. Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension. Life Sci, 2016, 159: 104-110.
27.	Stearman RS, Cornelius AR, Lu X, et al. Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2014, 189(9): 1110-1120.
28.	Pepke-Zaba J, Ghofrani HA, Hoeper MM. Medical management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev, 2017, 26(143): 160107.
29.	Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest, 2008, 134(2): 229-236.
30.	Ja?s X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol, 2008, 52(25): 2127-2134.
31.	Hitzerd E, Neuman RI, Broekhuizen M, et al. Transfer and vascular effect of endothelin receptor antagonists in the human placenta. Hypertension, 2020, 75(3): 877-884.
32.	Ghofrani HA, Simonneau G, D'Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med, 2017, 5(10): 785-794.
33.	Heresi GA, Love TE, Tonelli AR, et al. Choice of initial oral therapy for pulmonary arterial hypertension: age and long-term survival. Am J Respir Crit Care Med, 2018, 198(8): 1090-1093.
34.	Escribano-Subias P, Bendjenana H, Curtis PS, et al. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulm Circ, 2019, 9(2): 2045894019846433.
35.	Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med, 2013, 369(4): 319-329.
36.	Simonneau G, D'Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). N Engl J Med, 2015, 45(5): 1293-1302.
37.	Marra AM, Halank M, Benjamin N, et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res, 2018, 19(1): 258.
38.	McLaughlin VV, Jansa P, Nielsen-Kudsk JE, et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm Med, 2017, 17(1): 216.
39.	Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 2002, 347(5): 322-329.
40.	Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med, 2021, 384(4): 325-334.
41.	Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med, 2019, 7(3): 239-248.
42.	Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg, 2010, 139(1): 85-91.
43.	Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation, 2009, 120(13): 1248-1254.
44.	Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest, 2003, 123(2): 338-343.
45.	Kunihara T, Wilkens H, Halank M, et al. Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy. Eur J Cardiothorac Surg, 2021, 60(4): 840-847.

1. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 2019, 53(1): 1801913.
2. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J, 2016, 37(1): 67-119.
3. Simonneau G, Torbicki A, Dorfmüller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev, 2017, 26(143): 160112.
4. Papamatheakis DG, Poch DS, Fernandes TM, et al. Chronic Thromboembolic Pulmonary Hypertension: JACC Focus Seminar. J Am Coll Cardiol, 2020, 76(18): 2155-2169.
5. Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest, 2001, 119(3): 818-823.
6. Taniguchi Y, Ja?s X, Jevnikar M, et al. Predictors of survival in patients with not-operated chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant, 2019, 38(8): 833-842.
7. 中華醫學會呼吸病學分會肺栓塞與肺血管病學組, 中國醫師協會呼吸醫師分會肺栓塞與肺血管病工作委員會, 全國肺栓塞與肺血管病防治協作組, 等. 中國肺動脈高壓診斷與治療指南(2021版). 中華醫學雜志, 2021, 101(1): 11-51.
8. Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution's experience of more than 2, 700 patients. Ann Thorac Surg, 2012, 94(1): 97-103.
9. Cannon JE, Su L, Kiely DG, et al. Dynamic risk stratification of patient long-term outcome after pulmonary endarterectomy. Circulation, 2016, 133(18): 1761-1771.
10. Hu S, Tan JS, Liu S, et al. The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China. J Thromb Thrombolysis, 2022, 53(4): 926-933.
11. Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J, 2019, 53(1): 1801915.
12. Aoki T, Sugimura K, Tatebe S, et al. Comprehensive evaluation of the effectiveness and safety of balloon pulmonary angioplasty for inoperable chronic thrombo-embolic pulmonary hypertension: long-term effects and procedure-related complications. Eur Heart J, 2017, 38(42): 3152-3159.
13. Ja?s X, Brenot P, Bouvaist H, et al. Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med, 2022, 10(10): 961-971.
14. Sommer N, Ghofrani HA, Pak O, et al. Current and future treatments of pulmonary arterial hypertension. Br J Pharmacol, 2021, 178(1): 6-30.
15. Mitchell JA, Kirkby NS. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol, 2019, 176(8): 1038-1050.
16. Seo B, Oemar BS, Siebenmann R, et al. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation, 1994, 89(3): 1203-1208.
17. Dai Y, Chen X, Song XX, et al. Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension. J Am Coll Cardiol, 2019, 73(20): 2567-2580.
18. Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ (Clinical research ed), 2018, 360: j5492.
19. Zolty R. Pulmonary arterial hypertension specific therapy: The old and the new. Pharmacol Ther, 2020, 214: 107576,epub.
20. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation, 2011, 123(20): 2263-2273.
21. Pichl A, Sommer N, Bednorz M, et al. Riociguat for treatment of pulmonary hypertension in COPD: a translational study. Eur Respir J, 2019, 53(6): 1802445.
22. Kim NH. Group 4 pulmonary hypertension: chronic thromboembolic pulmonary hypertension: epidemiology, pathophysiology, and treatment. Cardiol Clin, 2016, 34(3): 435-441.
23. Howden EJ, Ruiz-Carmona S, Claeys M, et al. Oxygen pathway limitations in patients with chronic thromboembolic pulmonary hypertension. Circulation, 2021, 143(21): 2061-2073.
24. Miao R, Dong XB, Gong JN, et al. Examining the development of chronic thromboembolic pulmonary hypertension at the single-cell level. Hypertension, 2022, 79(3): 562-574.
25. Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J, 2013, 41(2): 462-468.
26. Southwood M, MacKenzie Ross RV, Kuc RE, et al. Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension. Life Sci, 2016, 159: 104-110.
27. Stearman RS, Cornelius AR, Lu X, et al. Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension. Am J Respir Crit Care Med, 2014, 189(9): 1110-1120.
28. Pepke-Zaba J, Ghofrani HA, Hoeper MM. Medical management of chronic thromboembolic pulmonary hypertension. Eur Respir Rev, 2017, 26(143): 160107.
29. Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest, 2008, 134(2): 229-236.
30. Ja?s X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol, 2008, 52(25): 2127-2134.
31. Hitzerd E, Neuman RI, Broekhuizen M, et al. Transfer and vascular effect of endothelin receptor antagonists in the human placenta. Hypertension, 2020, 75(3): 877-884.
32. Ghofrani HA, Simonneau G, D'Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med, 2017, 5(10): 785-794.
33. Heresi GA, Love TE, Tonelli AR, et al. Choice of initial oral therapy for pulmonary arterial hypertension: age and long-term survival. Am J Respir Crit Care Med, 2018, 198(8): 1090-1093.
34. Escribano-Subias P, Bendjenana H, Curtis PS, et al. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulm Circ, 2019, 9(2): 2045894019846433.
35. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med, 2013, 369(4): 319-329.
36. Simonneau G, D'Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). N Engl J Med, 2015, 45(5): 1293-1302.
37. Marra AM, Halank M, Benjamin N, et al. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). Respir Res, 2018, 19(1): 258.
38. McLaughlin VV, Jansa P, Nielsen-Kudsk JE, et al. Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study. BMC Pulm Med, 2017, 17(1): 216.
39. Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med, 2002, 347(5): 322-329.
40. Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med, 2021, 384(4): 325-334.
41. Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med, 2019, 7(3): 239-248.
42. Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg, 2010, 139(1): 85-91.
43. Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation, 2009, 120(13): 1248-1254.
44. Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest, 2003, 123(2): 338-343.
45. Kunihara T, Wilkens H, Halank M, et al. Haemodynamic benefit of bridging use of bosentan prior to pulmonary endarterectomy. Eur J Cardiothorac Surg, 2021, 60(4): 840-847.

Previous Article
核因子E2相關因子2在慢性阻塞性肺疾病中的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

肺動脈高壓靶向藥物在慢性血栓栓塞性肺動脈高壓中的應用現狀

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content